Last reviewed · How we verify
Basal-bolus detemir-aspart insulin regimen
Basal-bolus detemir-aspart insulin regimen is a Small molecule drug developed by Centre Europeen d'Etude du Diabete. It is currently FDA-approved. Also known as: Levemir, Novorapid.
At a glance
| Generic name | Basal-bolus detemir-aspart insulin regimen |
|---|---|
| Also known as | Levemir, Novorapid |
| Sponsor | Centre Europeen d'Etude du Diabete |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes (PHASE3)
- Detemir Energy Expenditure Study (PHASE4)
- A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus (PHASE3)
- Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (PHASE3)
- Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes (PHASE4)
- Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes (PHASE4)
- Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes (PHASE4)
- Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Basal-bolus detemir-aspart insulin regimen CI brief — competitive landscape report
- Basal-bolus detemir-aspart insulin regimen updates RSS · CI watch RSS
- Centre Europeen d'Etude du Diabete portfolio CI
Frequently asked questions about Basal-bolus detemir-aspart insulin regimen
What is Basal-bolus detemir-aspart insulin regimen?
Basal-bolus detemir-aspart insulin regimen is a Small molecule drug developed by Centre Europeen d'Etude du Diabete.
Who makes Basal-bolus detemir-aspart insulin regimen?
Basal-bolus detemir-aspart insulin regimen is developed and marketed by Centre Europeen d'Etude du Diabete (see full Centre Europeen d'Etude du Diabete pipeline at /company/centre-europeen-d-etude-du-diabete).
Is Basal-bolus detemir-aspart insulin regimen also known as anything else?
Basal-bolus detemir-aspart insulin regimen is also known as Levemir, Novorapid.
What development phase is Basal-bolus detemir-aspart insulin regimen in?
Basal-bolus detemir-aspart insulin regimen is FDA-approved (marketed).
Related
- Manufacturer: Centre Europeen d'Etude du Diabete — full pipeline
- Also known as: Levemir, Novorapid
- Compare: Basal-bolus detemir-aspart insulin regimen vs similar drugs
- Pricing: Basal-bolus detemir-aspart insulin regimen cost, discount & access